Parameters associated with iron chelation treatment
| Patient . | DFP treatment . | Blood parameters at month 0 → month 6 . | ||||||
|---|---|---|---|---|---|---|---|---|
| ID . | Age, y . | Sex . | Dose mg/kg/d . | Mo . | Hct, % . | Hb level, g/dL . | Serum iron level, μmol/L . | Ferritin level, μg/L . |
| A | 15 | F | 30 | 6 | 38.0 → 37.9 | 13.5 → 12.8 | 18.5 → 17.5 | 117 → 37.6 |
| B | 23 | F | 20 | 6 | 40.9 → 34.1 | 13.5 → 10.8 | 7.2 → 5.6 | 12.0 → 13.0 |
| C | 14 | M | 20 | 6 | 43.3 → 43.7 | 14.2 → 14.7 | 14.4 → 13.1 | 106 → 13.0* |
| D | 18 | M | 20 | 6 | 43.9 → 42.5 | 16.1 → 15.7 | 16.6 → 15.8 | 19.0 → 13.6 |
| E | 17 | F | 20 | 6 | 34.8 → 32.8 | 12.9 → 10.2 | 7.1 → 2.9 | 8.0 → 2.0 |
| F | 13 | M | 20 | 6 | 39,0 → 38.0 | 13.4 → 12.3 | 12.3 → 12.0 | 16.0 → 9.0 |
| G | 20 | F | 20 | 6 | 40.4 → 37.0 | 14.0 → 12.6 | 27.3 → 11.8 | 15.0 → 3.5 |
| H | 18 | F | 30 | 6 | 35.4 → 33.0 | 11.8 → 10.1 | 16.4 → 2.4 | 5.0 → 3.0 |
| I | 20 | F | 30 | 6 | 44.5 → 41.0 | 13.3 → 15.6 | 15.6 → 29.0 | 70 → 7.0* |
| Mean Δ±SD | 2.24 ± 2.17 | 1.31 ± 1.04 | 2.81 ± 8.43 | 29.6 ± 37.6 | ||||
| Relative mean Δ±SD | 0.06 ± 0.05 | 0.10 ± 0.08 | 0.18 ± 0.49 | 0.56 ± 0.32 | ||||
| p-tt significance P < | .0145† | .0053† | .425 | .070 | ||||
| 1-way Anova P <.01 | NS | NS | NS | NS | ||||
| Patient . | DFP treatment . | Blood parameters at month 0 → month 6 . | ||||||
|---|---|---|---|---|---|---|---|---|
| ID . | Age, y . | Sex . | Dose mg/kg/d . | Mo . | Hct, % . | Hb level, g/dL . | Serum iron level, μmol/L . | Ferritin level, μg/L . |
| A | 15 | F | 30 | 6 | 38.0 → 37.9 | 13.5 → 12.8 | 18.5 → 17.5 | 117 → 37.6 |
| B | 23 | F | 20 | 6 | 40.9 → 34.1 | 13.5 → 10.8 | 7.2 → 5.6 | 12.0 → 13.0 |
| C | 14 | M | 20 | 6 | 43.3 → 43.7 | 14.2 → 14.7 | 14.4 → 13.1 | 106 → 13.0* |
| D | 18 | M | 20 | 6 | 43.9 → 42.5 | 16.1 → 15.7 | 16.6 → 15.8 | 19.0 → 13.6 |
| E | 17 | F | 20 | 6 | 34.8 → 32.8 | 12.9 → 10.2 | 7.1 → 2.9 | 8.0 → 2.0 |
| F | 13 | M | 20 | 6 | 39,0 → 38.0 | 13.4 → 12.3 | 12.3 → 12.0 | 16.0 → 9.0 |
| G | 20 | F | 20 | 6 | 40.4 → 37.0 | 14.0 → 12.6 | 27.3 → 11.8 | 15.0 → 3.5 |
| H | 18 | F | 30 | 6 | 35.4 → 33.0 | 11.8 → 10.1 | 16.4 → 2.4 | 5.0 → 3.0 |
| I | 20 | F | 30 | 6 | 44.5 → 41.0 | 13.3 → 15.6 | 15.6 → 29.0 | 70 → 7.0* |
| Mean Δ±SD | 2.24 ± 2.17 | 1.31 ± 1.04 | 2.81 ± 8.43 | 29.6 ± 37.6 | ||||
| Relative mean Δ±SD | 0.06 ± 0.05 | 0.10 ± 0.08 | 0.18 ± 0.49 | 0.56 ± 0.32 | ||||
| p-tt significance P < | .0145† | .0053† | .425 | .070 | ||||
| 1-way Anova P <.01 | NS | NS | NS | NS | ||||
The table depicts the patients' sex and age and blood parameters at the beginning and at the end of the indicated 6-month period of treatment with deferiprone (DFP). The mean (absolute and relative) decrease (Δ) in values following treatment was NS at P < .01 for all 4 parameters using Bonferroni Anova 1-way test.
Hct indicates hematocrit; Hb, hemoglobin; p-tt, paired t test; and NS, not statistically significant.
The patients were recovering from a recent infective episode at inclusion.
The mean (absolute and relative) decrease (Δ) in values following treatment was significant (at the indicated P > values) for hct and for Hb values when using p-tt.